Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.65 +0.14 (+0.27%)

Delayed Quote Updated: 11:48 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends

October 01, 2026

From Genentech

Via Business Wire

Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions

October 01, 2026

From Genentech

Via Business Wire

Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine

October 01, 2026

From Genentech

Via Business Wire

Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market? ↗

September 30, 2026

Roche is increasingly looking like a notable contender in this fast-growing area.

Via The Motley Fool

Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis

September 30, 2026

From Genentech

Via Business Wire

Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon

September 28, 2026

From Genentech

Via Business Wire

Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)

September 23, 2026

From Genentech

Via Business Wire

Is Regeneron Stock a Bargain Below $800? ↗

September 22, 2026

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.

Via The Motley Fool

Topics Intellectual Property

Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity

September 22, 2026

From Genentech

Via Business Wire

BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗

September 18, 2026

BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

Via The Motley Fool

Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center

September 17, 2026

From Genentech

Via Business Wire

Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study

September 17, 2026

From Genentech

Via Business Wire

U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments

September 10, 2026

From Genentech

Via Business Wire

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

Via Investor Brand Network

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

From BioMedWire

Via GlobeNewswire

Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗

September 04, 2026

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Via MarketBeat

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

This biotech stock looks like a great candidate to buy on the admittedly steep dip.

Via The Motley Fool

2 Stocks That Could Capitalize on the GLP-1 Boom ↗

August 25, 2026

They aren't the most prominent names in the GLP-1 space, but they are worth a second look.

Via The Motley Fool

Genentech Announces Manufacturing Expansion in Hillsboro, Oregon

August 20, 2026

From Genentech

Via Business Wire

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

August 18, 2026

From Genentech

Via Business Wire

2 GLP-1 Stocks That Could Double Your Money by 2031 ↗

August 16, 2026

They are fairly risky, but their potential upside is massive.

Via The Motley Fool

Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help. ↗

August 14, 2026

Want to put your money into global stocks that might be big winners from AI? These two low-cost ETFs offer international diversification.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy

July 15, 2026

From Genentech

Via Business Wire

Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗

July 11, 2026

There are good reasons to invest in Lilly and to hold off.

Via The Motley Fool

VYMI vs. VIGI: Which International Dividend ETF Is Better? ↗

July 09, 2026

When buying international dividend stocks, diversification is likely the best bet.

Via The Motley Fool

Topics Artificial Intelligence ETFs

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger ↗

July 08, 2026

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

Via MarketBeat

Topics Artificial Intelligence ETFs Stocks

Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

July 07, 2026

From Genentech

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.